Inovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of Tumor

Inovio’s Voceryq will compete with a Precigen product that last year became the first FDA-approved drug for recurrent respiratory papillomatosis, or RRP. While the two immunotherapies carry the same $460,000 list price, Inovio executives claim their product has another competitive advantage. The post Inovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of Tumor…

Read More

7 Potential Problems with Medicare’s AI Prior Authorization Experiment 

The federal government is testing whether artificial intelligence can help Medicare identify unnecessary medical care, speed up the prior authorization process, and reduce healthcare spending. But a new report based on evidence recovered from a lawsuit raises concerns about the AI experiment. The post 7 Potential Problems with Medicare’s AI Prior Authorization Experiment  appeared first…

Read More

Integris Health to Join Risant Health as Health System Dealmaking Stays Active

As health system dealmaking stays steady in 2026, Integris Health is joining Risant Health to accelerate value-based care. The partnership represents an integration of Risant Health’s capabilities into Integris’ existing system, rather than a traditional merger. The post Integris Health to Join Risant Health as Health System Dealmaking Stays Active appeared first on MedCity News.

Read More